Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510244755

Publication Date:

October 29, 2024

Pages:

105

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
The global market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics was estimated to be worth US$ 14620 million in 2023 and is forecast to a readjusted size of US$ 38900 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by region & country, by Type, and by Application.
The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics.
麻豆原创 Segmentation
By Company
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Segment by Type:
Therapeutics
Diagnostics
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Introduction
1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics 麻豆原创 Size Forecast
1.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics 麻豆原创 Trends & Drivers
1.3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Trends
1.3.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics 麻豆原创 Drivers & Opportunity
1.3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics 麻豆原创 Challenges
1.3.4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players Revenue Ranking (2023)
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Company (2019-2024)
2.3 Key Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
2.6 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics 麻豆原创 Competitive Analysis
2.6.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Therapeutics
3.1.2 Diagnostics
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type
3.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Type (2019-2030)
3.2.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application
4.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Application (2019-2030)
4.2.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region
5.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2019-2024)
5.1.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2025-2030)
5.1.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
5.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
5.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
5.4.2 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
5.5.2 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
5.6.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value
6.3 United States
6.3.1 United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
6.3.2 United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
6.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
6.6.2 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
6.7.2 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
6.8.2 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030
6.9.2 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Siemens Healthcare
7.1.1 Siemens Healthcare Profile
7.1.2 Siemens Healthcare Main Business
7.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.1.4 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.1.5 Siemens Healthcare Recent Developments
7.2 Celerion
7.2.1 Celerion Profile
7.2.2 Celerion Main Business
7.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.2.4 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.2.5 Celerion Recent Developments
7.3 ZyVersa Therapeutics, Inc.
7.3.1 ZyVersa Therapeutics, Inc. Profile
7.3.2 ZyVersa Therapeutics, Inc. Main Business
7.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.3.4 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.3.5 Cisbio Recent Developments
7.4 Cisbio
7.4.1 Cisbio Profile
7.4.2 Cisbio Main Business
7.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.4.4 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.4.5 Cisbio Recent Developments
7.5 Regeneron Pharmaceuticals, Inc.
7.5.1 Regeneron Pharmaceuticals, Inc. Profile
7.5.2 Regeneron Pharmaceuticals, Inc. Main Business
7.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.5.4 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.5.5 Regeneron Pharmaceuticals, Inc. Recent Developments
7.6 BioPredictive
7.6.1 BioPredictive Profile
7.6.2 BioPredictive Main Business
7.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.6.4 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.6.5 BioPredictive Recent Developments
7.7 Echosens
7.7.1 Echosens Profile
7.7.2 Echosens Main Business
7.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.7.4 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.7.5 Echosens Recent Developments
7.8 Genfit
7.8.1 Genfit Profile
7.8.2 Genfit Main Business
7.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.8.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.8.5 Genfit Recent Developments
7.9 Enterome
7.9.1 Enterome Profile
7.9.2 Enterome Main Business
7.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.9.4 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.9.5 Enterome Recent Developments
7.10 NGM Biopharmaceuticals
7.10.1 NGM Biopharmaceuticals Profile
7.10.2 NGM Biopharmaceuticals Main Business
7.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions
7.10.4 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)
7.10.5 NGM Biopharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industrial Chain
8.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.